[East China Pharmaceutical: subsidiary Maihuatinib tablets included in Breakthrough Therapeutic Drug Program]-- East China Medicine announcement, according to the public information issued by the Drug Evaluation Center of the State Drug Administration Hangzhou Zhongmei East China Pharmaceutical Co., Ltd., a wholly owned subsidiary of the company, has introduced Maihuatinib tablets into the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) with rare mutations in epidermal growth factor receptor.